Home | Breaking Out | AI powered stock trade ideas | Bullish Engulfing | Market Signals | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart

StockChartsAI.com

All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.


Stock Charts AI Power Rank: 8.2
Power Rank trending -> DOWN

Last Price: 474.95 - Change: 6.24 - Change %: 1.3313
06/24/2024 16:01:00 EST

Vertex Pharmaceuticals Inc (VRTX)

Industry: Biotechnology

Price Support Resistance

In the past 20 trading days, VRTX has been trading in a range between $485.53 and $441.13 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

VRTX is trading below resistance at $485.53, about 2% to the upside. There is support at $430.11 -9% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

Vertex Pharmaceuticals Inc $VRTX entered a Green zone 33 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $388.67, a potential down side of -18.17% from the recent price of 474.95. The stock is trading 2.42% (potential upside) below its 52 week high of $486.43 and 41.43 % (potential downside) above its 52 week low of $335.82 - based on the recent price.

Company Summary

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.

VRTX Website

News

Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.
Source: The Motley Fool
Tue, 25 Jun 2024 04:12:00 -0400
Sentiment: Positive
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $474.95, signifying a +1.33% move from its prior day's close.
Source: Zacks Investment Research
Mon, 24 Jun 2024 19:05:40 -0400
Sentiment: Neutral
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Source: Zacks Investment Research
Mon, 24 Jun 2024 10:50:19 -0400
Sentiment: Positive
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive.
Source: Business Wire
Fri, 21 Jun 2024 15:45:00 -0400
Sentiment: Neutral
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
This magnificent drugmaker is much smaller than Eli Lilly, but is still large and successful. It has massive growth opportunities in multiple markets.
Source: The Motley Fool
Fri, 21 Jun 2024 05:51:00 -0400
Sentiment: Positive
Instituions Institution %: 95.741
Last QTR Institution change: 4456913

Insiders
Insiders %: 0.103
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 67910
Insiders Net last QTR: -67910

Analyst Ratings
Target Price: 388.67
Overall Rating: 3.9355
Strong Buys (5): 14
Buys (4): 6
Holds (3): 8
Sells (2): 1
Strong Sells (1): 2

Technicals
52 Week Hi: 486.43
52 Week Low: 335.82
Beta: 0.413
50 Day MA: 435.999
200 Day MA: 402.304

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0.565
Qtr Revenue Growth YOY: 0.133
Forward PE: 24.3309
Trailing PE: 30.8609

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!

1000

Stock Analyzed Each Night

Portfolio

Easily Upload Track Your Stocks

Trends

See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.